Peijia Medical's partner JenaValve was fully acquired by Edwards Lifesciences, opening a new chapter in transcatheter treatment of aortic regurgitation
Friday, July 26, 2024
JenaValve Technology, Inc. (hereinafter referred to as JenaValve), a partner of Peijia Medical (9996.HK), announced that it had reached an agreement with Edwards Lifesciences (NYSE: EW, referred to as "Edwards"), a US medical device giant, to acquire JenaValve. After the transaction is completed, Peijia Medical will continue to have exclusive rights to the JenaValve Trilogy THV system in Greater China.
On March 28, 2024, the 1-year clinical data of the key clinical trial ALIGN-AR of the JenaValve Trilogy™ heart valve system, which has the world's first locators design and is used to treat aortic valve regurgitation, was published in the famous medical journal The Lancet. The results of the trial are encouraging. The publication of the ALIGN-AR trial data is undoubtedly an important milestone in the treatment of aortic valve regurgitation with transcatheter aortic valve replacement, and will create a new era of minimally invasive interventional treatment for patients with high-risk surgical symptomatic moderate to severe or severe aortic valve regurgitation.
At the end of 2021, Peijia Medical and JenaValve signed an exclusive license for the Trilogy™️ heart valve system in Greater China, and Peijia Medical became a minority shareholder of JenaValve. Subsequently, Peijia Medical renamed the technology trademark to TaurusTrio™️ transcatheter aortic valve system, conducted a registered clinical trial in China, and successfully completed the enrollment of all patients in January 2024, entering the one-year follow-up stage.
"As a partner of JenaValve, Peijia Medical congratulates JenaValve and Edwards Lifesciences on their announcement of a transformative collaboration in the field of structural heart," said Dr. Yi Zhang, Chairman and CEO of Peijia Medical. The ALIGN-AR trial results were published in The Lancet, which quickly changed the perception of doctors around the world about aortic regurgitation treatment options. Edwards' high-priced acquisition of JenaValve is the highest recognition of the product, technology and therapy, and will greatly promote the rapid development of interventional treatment for aortic regurgitation around the world.
According to the acquisition agreement, after the transaction is completed, Peijia Medical will continue to have exclusive authorization for the JenaValve Trilogy THV system in Greater China. The acquisition of the product by industry giant Edwards Lifesciences will enhance global doctors' understanding of aortic valve regurgitation disease and accelerate the development of the JenaValve Trilogy THV system. After the transaction is completed, the company will work hand in hand with Edwards Lifesciences to provide the latest and best surgical solutions for aortic valve regurgitation patients in their respective markets around the world.
This acquisition marks another breakthrough for Edwards in its transcatheter valve product pipeline. It has perfected its layout and made significant progress in several recent hot spots in the valve field, including tricuspid valve replacement, mitral valve therapy, life cycle management/long-term valve, aortic valve regurgitation, etc. As a leading company in the interventional treatment of structural heart disease in China, Peijia Medical has also proactively and completely laid out the following hot spots: transvascular tricuspid valve replacement MonarQ, transseptal mitral valve replacement HighLife, mitral/tricuspid valve edge-to-edge repair GeminiOne, long-term stem valve TaurusNXT and polymer valve and aortic valve regurgitation TaurusTrio, etc., to continuously meet the large clinical needs of doctors and patients at home and abroad for transcatheter valve treatment products.
As an innovative company in the field of structural heart disease, Peijia Medical has started the technical layout of treating aortic regurgitation many years ago. Now with the release of evidence-based treatment, the outbreak seems to be a natural outcome, but it is inseparable from the technical understanding and strategic vision of the company's early management. We always believe that a deep understanding of technology can not only help the uniqueness and competitiveness of the pipeline, but also improve the success rate of external investment. We have a complete pipeline that can compete with international giants, and we also look forward to more products in our pipeline to bear fruit faster.
"We look forward to establishing meaningful and productive relationships with international peers such as Edwards. We also expect industry giants to turn their attention to tricuspid valve replacement products such as MonarQ, in which Peijia Medical has full rights, and GeminiOne, a Yuan-to-Yuan repair product developed entirely by a local team." Dr. Zhang Yi said, "We have great confidence in China's R&D capabilities. We will surely reach that step successfully with gradual progress and continuous efforts!"
Source: peijiamedical.com